Jun 04, 2020
Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020
Jun 02, 2020
RenovoRx Announces Orphan Drug Designation Granted for Treating Bile Duct Cancer
Apr 19, 2020
Innovent Biologics Announces FDA Approval of Pemazyre(TM) (Pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
Apr 17, 2020
FDA Approves First Targeted Treatment for Patients with Cholangiocarcinoma, a Cancer of Bile Ducts
Nov 13, 2019
Moderate Dose Chemotherapy Doubles Survival Rate in All Ages
Nov 07, 2019
TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma
Oct 20, 2019
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
Aug 12, 2019
Consumer Health Tech Company Ciitizen and Cholangiocarcinoma Foundation Announce Partnership Enabling Early Access for Cholangiocarcinoma Patients to Ciitizen's Private Beta
May 23, 2019
Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint
May 16, 2019
Sirnaomics Publishes Data for Lead Candidate STP705 in Cancer Model as 2019 American Society of Clinical Oncology Annual Meeting Online Abstract
Apr 28, 2019
China National Medical Products Administration Approves Sinovant's Clinical Trial Application for Derazantinib
Apr 01, 2019
Preclinical Data Demonstrates the Potential of QED Therapeutics' Infigratinib in Multiple FGFR+ Tumor Types
Feb 18, 2019
Global Cholangiocarcinoma (CCA) Market Insights 2017-2019 & 2028 - Disease Understanding, Epidemiology, Segmentation, Management, Outlook, & Drugs Uptake
Dec 10, 2018
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Dec 10, 2018
QED Therapeutics Announces a Collaboration with Foundation Medicine to Develop Companion Diagnostics for Infigratinib
Nov 02, 2018
Global Bile Duct Cancer Market and Competitive Report 2018: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, and Market Shares2014-2023
Oct 19, 2018
QED Therapeutics Presents Data for Infigratinib in Cholangiocarcinoma in Late Breaking Abstract at the European Society of Medical Oncology 2018 Congress
Sep 11, 2018
Global Primary Sclerosing Cholangitis Treatment Market 2018-2022: Key Vendors are Allergan, Glenmark, Impax Laboratories, Mylan & Teva Pharmaceuticals
Aug 16, 2018
Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of Cholangiocarcinoma
Jan 30, 2018
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing